A study has been released that 34 new drugs, including the peripheral T-cell lymphoma treatment Beleodaq, are urgently needed to be introduced in Korea. These new drugs have not been introduced because they are judged to be insufficient in marketability due to domestic screening permits.

KoNECT announced that it will select 34 new drugs that are urgently needed to be introduced in Korea and release them online on the 18th for the 2022 KoNECT Brief 1. KoNECT derived priorities through preliminary analysis of 244 in Korea. As a result, Beleodaq (peripheral T cell lymphoma treatment), Palynziq, Zinplava (lostridium difficile recurrence reduction effect), Artesunate (severe malaria treatment), and Xerava (c